{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029956","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.553094+00:00","generated_at":"2026-06-04T23:00:07.861650+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside Biomedical Q4 2023 net loss narrows to $4.8M; cash runway to Q3 2025","bullets":["Net loss Q4 2023 of $4.8M ($0.08/shr) improved from $9.7M loss ($0.16/shr) in Q4 2022.","License revenue Q4 2023 of $6.3M, up from $0.3M, driven by $5M BioCryst upfront and $1M Aura milestone.","Cash $28.9M at Dec 31; subsequent $15M equity offering extends runway into Q3 2025.","Phase 2b ODYSSEY wet AMD trial topline data expected Q3 2024; randomization completed Dec 2023.","Full year 2023 net loss $32.5M ($0.53/shr) vs $32.9M ($0.55/shr) in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029956","json":"https://secwatch.observer/filing/0000950170-24-029956.json","markdown":"https://secwatch.observer/filing/0000950170-24-029956.md","text":"https://secwatch.observer/filing/0000950170-24-029956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/0000950170-24-029956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/clsd-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:00:07.861650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"96e757b872855719ed82bc258c37ca5560b64e9e","claim":"Clearside Biomedical, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $6.3 million, net income Net loss for the fourth quarter of 2023 was $4.8 million, EPS $0.08 per share.","evidence_excerpt":"the first patient in the CoMpass trial in December 2023. Fourth Quarter 2023 Financial Results • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022. The $6.0 million increase was primarily attributable to the receipt of $5.0 million in an upfront license fee from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017024029956/0000950170-24-029956-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$6.3 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 was $4.8 million"},{"label":"EPS","value":"$0.08 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}